论文部分内容阅读
作者为了解口服阿曲南(aztrconam)的疗效,对美国去墨西哥旅游成人患急性腹泻者进行双盲法研究。对象和方法受试者共191例,年龄为18—60岁,女性占49％。将其随机分为两组。其中安慰剂组93例,口服阿曲南组98例。受试者必须在起病72h以内,大便在24h内4次以上或在8h内有3次未成形便,也必须至少具备其它一些症状如腹痛、肌肉痉挛,恶心呕吐或发热。但必须除外怀孕或哺乳者;β—内酰胺抗生素过敏者,肝功异常、胃酸缺乏,肠道疾病或有任何潜在性内科疾病者。也除外5d内曾服用过抗肠道病原体抗生素。所有受试者在治疗前后行大便、周围血、尿和血清生化检查。92％患者得到随访。
To understand the efficacy of oral aztreonam, the authors conducted a double-blind study of adults with acute diarrhea in adults traveling to Mexico. Subjects and methods A total of 191 subjects, aged 18-60 years old, 49% of women. They were randomly divided into two groups. 93 cases in the placebo group and 98 cases in the atlantan group. Subjects must be within 72 hours of onset, stool more than 4 times in 24h or 3 times in 8h unformed, must also have at least some other symptoms such as abdominal pain, muscle cramps, nausea and vomiting or fever. But must be excluded from pregnancy or lactation; persons allergic to beta-lactam antibiotics, abnormal liver function, achlorhydria, intestinal disorders or any underlying medical condition. In addition to anti-intestinal pathogen antibiotics have also been taken within 5d. All subjects underwent biochemical tests of stool, peripheral blood, urine and serum before and after treatment. 92% of patients were followed up.